Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | Are we moving away from transplantation for the treatment of myeloma?

Fredrik Schjesvold • 10 Jun 2022

EHA 2022

Multiple Myeloma Antibodies Bortezomib CAR-T Ciltacabtagene autoleucel Daratumumab Dexamethasone Lenalidomide

CARTITUDE-6 DETERMINATION

Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, shares some insights into the future treatment landscape of multiple myeloma, drawing focus on the role of transplantation and whether treatment will move away from this approach. Dr Schjesvold highlights the DETERMINATION trial (NCT01208662) and also mentions upcoming trials investigating this, as well as the role of bispecifics in the future of myeloma therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Honoraria/advisory boards Sanofi, Amgen, Janssen

Replacing dexamethasone in transplant-ineligible multiple myeloma: the REST study

Fredrik Schjesvold • 11 Dec 2023

The REMNANT study: will treating patients at MRD relapse improve survival outcomes?

Fredrik Schjesvold • 11 Dec 2023

A Phase I study of WVT078, a BCMA×CD3 bsAb, with a gamma-secretase inhibitor (WHG626) in R/R MM

Fredrik Schjesvold • 11 Dec 2023

Melflufen/dex versus pom/dex in patients with R/R multiple myeloma without previous transplant

Fredrik Schjesvold • 11 Dec 2023

Related Videos

The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma

Faith Davies • 9 Apr 2024

Upcoming studies investigating linvoseltamab in myeloma

Faith Davies • 9 Apr 2024

Molecular characteristics associated with increased risk of disease progression in SMM

Mark Bustoros • 27 Sep 2023

Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia

Mark Bustoros • 27 Sep 2023